London - The multibillion- pound pharmaceutical industry has spent the last decade developing new drugs which have produced little benefit and caused considerable harm, experts say.
The claim that there is an “innovation crisis” in pharmaceuticals because of the difficulty and expense of discovering new drugs is a myth fostered by an industry whose chief focus is on marketing, they add.
Counter to drug industry claims that the pipeline of new drugs is running dry, the number of new drugs being licensed each year has remained at between 15 and 25. But most involve minor tweaks to existing drugs, designed to grab a slice of an existing market rather than offering genuine therapeutic innovation.
Independent reviews suggest that 85 to 90 percent provide little benefit over existing treatments, with some causing serious side effects which led to their withdrawal.
Writing in the British Medical Journal, Professor Donald Light from the University of Medicine of New Jersey and Joel Lexchin from York University in Toronto say the situation has remained the same for 50 years. The incentives for drug development are wrong and have skewed the behaviour of the industry.
“This is the real innovation crisis: pharmaceutical research and development turns out mostly minor variations on existing drugs and most new drugs are not superior on clinical measures. [They] have also produced an epidemic of serious adverse reactions that have added to national health-care costs,” they say.
More is spent on marketing (25 percent of revenues) than on discovering new molecules (1.3 percent). Drug industry claims that the cost of bringing a new drug to market is £1 billion (about R12.75bn) and is unsustainable are exaggerated, they claim. Research and development costs did rise substantially between 1995 and 2010 by £21.9bn, they concluded, but revenues increased six times faster – by £128bn.
The authors call for licensing authorities to stop approving new drugs of little therapeutic value.
The European Medicines Agency, which licenses drugs in the UK and Europe, keeps certain data about their safety and efficacy secret. Yet 29 percent of new biological agents approved by the agency received safety warnings within the first 10 years.
In a second paper, researchers from the London School of Economics argue that drug manufacturers should be made to demonstrate that their products are superior to existing treatments before being granted a licence, rather than, as now, superior only to a placebo.
“Changing the nature of regulation could encourage manufacturers to concentrate on the development of new drugs in therapeutic areas with few alternatives,” they say.
Stephen Whitehead, chief executive of the Association of the British Pharmaceutical Industry, said: “We strongly disagree with the claims made in these papers. Medical research has always rested on iterative and gradual innovation rather than breakthrough advances, which are very rare.
“If it were not for the incremental improvements made in the treatment of HIV, the disease would still be terminal rather than a manageable condition.” - The Independent